Phill Craig

Phill Craig is an accomplished business intelligence manager with extensive experience in the biotechnology sector, currently holding positions at Molecule to Medicine, Grey Wolf Therapeutics, Pathios Therapeutics, and ThirtyFiveBio since January 2022. With a strong foundation as a business analyst in these innovative companies, Phill Craig contributes to the development of novel therapies targeting cancer and immune responses. Previous roles include life science and healthcare consulting at DST Consulting, and a research associate position at Cambridge Healthcare Research focused on autoimmune biomarkers. Phill Craig also has a background in software development and product management, having served as head of product at Raveback. Academic credentials include a Master of Philosophy in Bioscience Enterprise from the University of Cambridge and a Bachelor of Science in Chemistry, complemented by degrees in International Business from the University of Otago and Université Jean Moulin.